News
Novo Nordisk (CPSE: NOVO B) Foundation Launches Pan-European Cardio Metabolic Bridge To Advance Obesity And Diabetes Pipeline
2+ hour, 22+ min ago (19+ words) The Foreign Policy Journal is a leading news publication covering US and international politics, business, and global affairs news....
EU Commits $580 Million As G7 Leaders Demand Coordinated Response To DRC Ebola Crisis
3+ day, 22+ hour ago (495+ words) By'Ewan Scott'|'Jun 18, 2026 | Featured, News & Analysis, Politics The European Commission has announced it is building on a support program worth approximately "493 million, or roughly $580 million, directed at humanitarian aid and health security amid the ongoing Ebola outbreak in the Democratic…...
New World Screwworm Detected In Texas For First Time Since 1966, Threatening $1. 8 Billion In Economic Damage
2+ week, 3+ day ago (503+ words) By'David Prior'|'Jun 5, 2026 | Featured, News & Analysis, Politics A case of New World screwworm has been confirmed in Zavala County, Texas, marking the first detection of the flesh-eating pest in the state since 1966. The U. S. Department of Agriculture's Animal and Plant Health…...
CVS Health (NYSE: CVS) Reinstates Zepbound Coverage And Adds New Weight-Loss Pill To Drug Plans
3+ week, 3+ day ago (427+ words) By'David Prior'|'May 29, 2026 | Economy & Business, Featured, News & Analysis CVS Health (NYSE: CVS) announced it will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin covering the anti-obesity pill Foundayo for millions of Americans on private insurance plans. Coverage of…...
CVS Health Restores Zepbound Coverage And Adds Eli Lilly's (LLY) New Obesity Pill To Preferred Drug List
3+ week, 3+ day ago (334+ words) By'David Prior'|'May 29, 2026 | Economy & Business, Featured, News & Analysis Eli Lilly (NYSE: LLY) received a significant boost after CVS Health announced it will once again cover the company's weight-loss drug Zepbound for eligible patients. CVS Health also confirmed it will add…...
Novo Nordisk (NVO) Faces Diverging Launch Dynamics As Oral GLP-1 Patterns Trail Injectable Performance
3+ week, 3+ day ago (19+ words) The Foreign Policy Journal is a leading news publication covering US and international politics, business, and global affairs news....
FDA Pushes Back Review Deadline For Astra Zeneca's Camizestrant Breast Cancer Drug Application
3+ week, 5+ day ago (19+ words) The Foreign Policy Journal is a leading news publication covering US and international politics, business, and global affairs news....
Hims and Hers (NYSE: HIMS) Launches Generic Semaglutide in Canada After Novo Nordisk Patent Lapse
4+ week, 1+ day ago (300+ words) By'Ewan Scott'|'May 24, 2026 | Economy & Business, Featured, News & Analysis Hims and Hers Health (NYSE: HIMS) has launched generic semaglutide in Canada, capitalising on a rare Novo Nordisk patent lapse that opened the country's GLP-1 market to lower-cost competition. Health Canada recently…...
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer's Drug Trajectory After Leqembi Updates
4+ week, 2+ day ago (312+ words) By'Timothy Mason'|'May 22, 2026 | Economy & Business, Featured, News & Analysis Biogen Inc. (NASDAQ: BIIB) was trading in a muted range on Friday, May 22, as the company continued to manage investor expectations around the commercial trajectory of Leqembi, its Alzheimer's drug. Leqembi, developed…...
Astra Zeneca [LSE: AZN] Shares Edge Higher After Winning NHS Approval for First Immunotherapy in Stomach Cancer
1+ mon, 1+ week ago (146+ words) The Foreign Policy Journal is a leading news publication covering US and international politics, business, and global affairs news....